Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.53 |
| ▸ | KHK | P50053 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24123774 | 0.86 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A | |
| SCHEMBL10203058 | 0.86 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A | |
| SCHEMBL25675681 | 0.84 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A | |
| SCHEMBL270283 | 0.84 | ADRB1 (0.62) | ADRB1HPGDHTR3EHTR3BHTR3A | |
| SCHEMBL12744643 | 0.83 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1HRH3MBTD1SIGMAR1 | |
| SCHEMBL14329223 | 0.83 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A | |
| SCHEMBL18311444 | 0.83 | ADRB1 (0.68) | L3MBTL3L3MBTL1KHKMBTD1ADRB1 | |
| SCHEMBL12666610 | 0.82 | KMT2A (0.56) | L3MBTL3L3MBTL1HRH3KMT2AMEN1 | |
| SCHEMBL25678723 | 0.81 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A | |
| SCHEMBL14850179 | 0.80 | ALDH1A1 (0.57) | L3MBTL3L3MBTL1HRH3MBTD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | ASANA BIOSCIENCES, LLC | 2023-01-26 | — | — | US | disclosed |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2020-06-11 | — | — | US | disclosed |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9896445-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | Ansana BioSciences, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896445-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | Ansana BioSciences, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170362216-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATEMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2017-12-21 | — | — | US | disclosed |
| US-20170362216-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATEMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2017-12-21 | — | — | US | disclosed |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362407-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-20160362407-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-20170362216-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATEMENT OF CANCER | KRAS, NRAS, RAF1 | L3MBTL3 1913/4885L3MBTL1 1459/4885KHK 1048/4885 |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-20160362406-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | L3MBTL3 1384/4885L3MBTL1 1200/4885KHK 1051/4885 |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | KRAS, NRAS, BRAF | L3MBTL3 2074/4885L3MBTL1 2417/4885KHK 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.